During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs.
Intravenous infusion of arginine vasopressin (AVP) depresses the slope of the ventilatory response to CO2 during acute hypercapnia. We therefore tested the hypothesis that AVP V1-receptor blockade would increase the slope of the ventilatory response to CO2. After a 20-min control period, an AVP V1-receptor antagonist (d(CH2)5[Tyr(Me)2]AVP) was injected into six conscious resting dogs. Thirty minutes after AVP V1-receptor blockade, dogs were exposed to sequential 20-min periods of 5 and 6.5% inspired CO2 in air. A second protocol (no AVP V1-receptor blockade) was conducted as a control. As predicted, AVP V1-receptor blockade enhanced ventilation during inhalation of 6.5% CO2 in association with an increased metabolic rate and increased plasma angiotensin II (ANG II). In eupneic dogs, stimulation of respiration by AVP V1-receptor blockade is mediated by ANG II. A third protocol with ANG II-receptor blockade (intravenous infusion of saralasin) combined with AVP V1-receptor blockade indicated that ANG II mediated the increase in metabolism and the augmented ventilation during inhalation of 6.5% CO2. We conclude that during acute hypercapnia of sufficient magnitude, and perhaps duration, AVP inhibits an ANG II-mediated stimulation of metabolism and respiration.
Walker
J K
JK
Department of Physiology, Queen's University, Kingston, Ontario, Canada.
Jennings
D B
DB
D000136:Acid-Base Equilibrium; D000208:Acute Disease; D000804:Angiotensin II / Q000378:metabolism / Q000502:physiology*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000008:administration & dosage*; D004285:Dogs; D018495:Fluid Shifts / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006935:Hypercapnia / Q000378:metabolism / Q000503:physiopathology*; D007262:Infusions, Intravenous; D008297:Male; D012083:Renin / Q000097:blood / Q000187:drug effects; D012119:Respiration / Q000187:drug effects* / Q000502:physiology; D012504:Saralasin / Q000008:administration & dosage
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D065092:Antidiuretic Hormone Receptor Antagonists; D000804:Angiotensin II; D001127:Arginine Vasopressin; D012083:Renin; D012504:Saralasin